Zobrazeno 1 - 10
of 352
pro vyhledávání: '"Warren RB"'
Autor:
Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC
Publikováno v:
The Lancet, 401(10370), 38-48. Elsevier Limited
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and pre
Autor:
Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R
Objectives: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease‑modifying ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::0ae8f298a66cfb33a4fb1de689e01e8c
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
Autor:
Soomro, M, Stadler, M, Dand, N, Bluett, J, Jadon, D, Jalali‐najafabadi, F, Duckworth, M, Ho, P, Marzo‐Ortega, H, Helliwell, PS, Ryan, AW, Kane, D, Korendowych, E, Simpson, MA, Packham, J, McManus, R, Gabay, C, Lamacchia, C, Nissen, MJ, Brown, MA, Verstappen, SMM, Van Staa, T, Barker, JN, Smith, CH, Chalmers, R, Flohr, C, Watson, K, Prieto‐Merino, D, Alabas, O, Barker, J, Becher, G, Bewley, A, Burden, D, Morrison, S, Laws, P, Evans, I, Griffiths, C, Ahmed, S, Kirby, B, Kleyn, E, Lawson, L, Mackenzie, T, McPherson, T, McElhone, K, Murphy, R, Ormerod, A, Owen, C, Reynolds, N, Rashid, A, Smith, C, Warren, R, Siebert, S, Brown, S, McAteer, H, Schofield, J, FitzGerald, O, McHugh, N, Warren, RB, Bowes, J, Barton, A
Objectives Psoriatic arthritis (PsA) has a strong genetic component, and the identification of genetic risk factors could help identify the ~30% of psoriasis patients at high risk of developing PsA. Our objectives were to identify genetic risk factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::f08440eaf5186fd6994b5803172b23bb
Publikováno v:
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::6bf0a578a9694e3f531fc2e38430e6ec
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8486
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8486
Autor:
Warren, RB, Lebwohl, M, Sofen, H, Piguet, V, Augustin, M, Brock, F, C Arendt, Fierens, F, Blauvelt, A
Publikováno v:
Journal of the European Academy of Dermatology and Venereology : JEADV, vol 35, iss 12
BackgroundCertolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumor necrosis factor biologic.ObjectivesTo report 3-year outcomes from the CIMPACT (NCT02346240) phase 3, CZP in moderate to severe plaque psoriasis, randomized controlled trial.Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::ef086d788a4cf4b047b27ffd2b4b173c
https://escholarship.org/uc/item/60q8t66g
https://escholarship.org/uc/item/60q8t66g
Autor:
Cro, S, Cornelius, VR, Pink, AE, Wilson, R, Pushpa-Rajah, A, Patel, P, Abdul-Wahab, A, August, S, Azad, J, Becher, G, Chapman, A, Dunnil, G, Ferguson, AD, Fogo, A, Ghaffar, SA, Ingram, JR, Kavakleiva, S, Ladoyanni, E, Leman, JA, Macbeth, AE, Makrygeoegou, A, Parslew, R, Ryan, AJ, Sharma, A, Shipman, AR, Sinclair, C, Wachsmuth, R, Woolf, RT, Wright, A, McAteer, H, Barker, JNWN, Burden, AD, Griffiths, CEM, Reynolds, NJ, Warren, RB, Lachmann, HJ, Capon, F, Smith, CH, APRICOT Study Group
Publikováno v:
The British journal of dermatology.
BACKGROUND Palmoplantar pustulosis (PPP) is a rare, debilitating, chronic inflammatory skin disease that affects the hands and feet. Clinical, immunological and genetic findings suggest a pathogenic role for interleukin (IL)-1. OBJECTIVES To determin
Autor:
Yiu, ZZN, Mason, KJ, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD, Study Group, BADBIR
Publikováno v:
The British Journal of Dermatology
Yiu, Z Z N, Mason, K J, Barker, J N W N, Hampton, P J, McElhone, K, Smith, C H, Warren, R B, Griffiths, C E M, Lunt, M & Burden, A D 2019, ' A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17849
Yiu, Z Z N, Mason, K J, Barker, J N W N, Hampton, P J, McElhone, K, Smith, C H, Warren, R B, Griffiths, C E M, Lunt, M & Burden, A D 2019, ' A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17849
Summary Background Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real‐world psoriasis population. Objectives Firstly, to investigate whether patient characteristics
Autor:
Warren, RB, Carrascosa, JM, Fumero, E, Schoenenberger, A, Lebwohl, MG, Szepietowski, JC, Reich, K
Publikováno v:
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background As treatment interruptions occur during psoriasis management in clinical practice, it is important to know the duration of clinical response after treatment withdrawal. Objectives To report time to and predictors of relapse in patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::05b9c2fa0afe0368bbd9eb9d81af8766
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3790
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3790
Autor:
Foulkes, AC, Watson, DS, Carr, DF, Kenny, JG, Slidel, T, Parslew, R, Pirmohamed, M, Consortium, PSORT, Anders, S, Reynolds, NJ, Griffiths, CEM, Warren, RB, Barnes, MR
Publikováno v:
PSORT Consortium 2019, ' A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis ', The Journal of investigative dermatology, vol. 139, no. 1, pp. 100-107 . https://doi.org/10.1016/j.jid.2018.04.041
J Invest Dermatol
JOURNAL OF INVESTIGATIVE DERMATOLOGY
J Invest Dermatol
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Biologic therapies have shown high efficacy in psoriasis, but individual response varies and is poorly understood. To inform biomarker discovery in the Psoriasis Stratification to Optimise Relevant Therapy (i.e., PSORT) study, we evaluated a comprehe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25d1f7f6b0c27c071487ce59f1e2e901
https://ora.ox.ac.uk/objects/uuid:93ee01fc-376c-4176-af28-f1de3ebf4bcf
https://ora.ox.ac.uk/objects/uuid:93ee01fc-376c-4176-af28-f1de3ebf4bcf
Autor:
Reich, K, Warren, RB, Iversen, L, Puig, L, Pau-Charles, I, Igarashi, A, Ohtsuki, M, Falques, M, Harmut, M, Rozzo, S, Lebwohl, MG, Cantrell, W, Blauvelt, A, Thaci, D
Publikováno v:
BRITISH JOURNAL OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. Objectives To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::74a80ee916f9ec7e460e4a8dae2a3180
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1485
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1485